Preview

Biodel Inc

Good Essays
Open Document
Open Document
1897 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
Biodel Inc
BUAD 490
3/14/13

Team Written Case Analysis (Concise)

Biodel, Inc.

BIODEL INC.
EXECUTIVE SUMMARY
Biodel’s use of biotechnology expertise in the three prime areas of Cell Biology, Molecular Biology, and Immunodiagnostics has led their company into some great opportunities. Biodel created a synthetic serum to replace fetal calf serum and horse serum, and provide a more consistently available product for scientific researchers. Biodel’s Molecular Biology division used DNA technology to gain 60% of the market share of growth factors and stock the largest collection of commercially available synthetic nucleotides, which was 50% of their sales. Biodel’s research and development in Immunodiagnostics led to the invention of DEMA, a non-radioactive method for measuring a wide array of biologically important substance.
The intelligence and vision of Dr. Oscar Feldman drove Biodel to a position of leadership in the biotechnology industry. Dr. Feldman has applied innovations in Cell Biology, Molecular Biology and Immunodiagnostics to increase market share for Biodel’s products. Dr. Feldman’s scientific friends and academic contacts offered Biodel high-quality technological advice and links to scientific community, and led to sophisticated research and development advances. Now the company is at a crossroad with decisions and direction necessary. In addition to strategic planning, the company would benefit from a modest re-structuring to streamline operations and prepare for unexpected events. Their future investments should be in areas where patent protection is likely, and in directions and projects that exploit their native expertise in molecular biology and genetic engineering. These technologies seem likely to transform health care in the next two decades. Having survived the threat of bankruptcy, Biodel now has a more balanced contract research portfolio and is poised to develop an even greater impact in the future.

CURRENT SITUATION

Biodel's

You May Also Find These Documents Helpful

  • Better Essays

    Gajardo, Gonzalo M., Patrick Sorgeloos, and John A. Beardmore. "Abstract." National Center for Biotechnology Information. U.S. National Library of Medicine, 28 Nov. 2006. Web. 04 Apr. 2013. .…

    • 1427 Words
    • 6 Pages
    Better Essays
  • Satisfactory Essays

    Biol

    • 287 Words
    • 2 Pages

    The workshop will be held at the BCIT Burnaby Campus in room 404/406, Building SE12. The Campus is located at 3700 Willingdon Avenue, Burnaby, BC. A map of the campus can be found at: http://www.bcit.ca/about/burnaby.shtml…

    • 287 Words
    • 2 Pages
    Satisfactory Essays
  • Powerful Essays

    Humans are on a constant quest in the search for perfection and advancement in all areas of life through progressive scientific knowledge. From such a stance, the future of humans appears boundless with all the potential possibilities biotechnology provides, but such developments will cause ethical, social and biological implications.…

    • 1631 Words
    • 7 Pages
    Powerful Essays
  • Better Essays

    Nucleon Case

    • 1217 Words
    • 5 Pages

    Nucleon, Inc. is one of over 200 firms founded since the 1970s which are focused on developing biotechnological pharmaceuticals products. Biotechnology came about with the development in advances of molecular biology and immunology, hence the new field of R&D is called “biotechnology”. Nucleons first product is CRP-1 (cell regulation ein-1) and after several years of experimentation the time was ready for human clinical trials, which was not going to be an easy hurdle to get over. Due to the fact that Nucleon did not have any manufacturing facilities which met the FDA requirements they had to figure out how to jump over the hurdles presented. One potion was to contract clinical manufacturing to an outside firm. Another option was to build a new pilot plant for clinical trials. Nucleons third option is to license the manufacturing to another biotechnology company. Risk was found in their options but they also came with rewards. If Nucleon could establish a strong paten on a important molecule this could ensure capital for growth and development which could keep Nucleon alive for years.…

    • 1217 Words
    • 5 Pages
    Better Essays
  • Good Essays

    Biopure’s Case Study

    • 804 Words
    • 4 Pages

    1. How do you assess Biopure’s potential in the human market? The animal market? According to the demand for RBCs which can be used to treat chronic anemia and blood loss is increasing, Biopure Corporation products have the chance to grow in the future market. Like the rest of the world, the US is an ageing society. Population ageing is the big problem in the US. Between 2000 and 2050, the number of older people is…

    • 804 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    Budget Proposal

    • 2559 Words
    • 11 Pages

    The Advanced Technology Program (2006). Federal Funding for Technological Revolutions: Biotechnology and Healthcare Highlights. Retrieved from http://www.atp.nist.gov/clso/biotech_healthcare.pdf…

    • 2559 Words
    • 11 Pages
    Powerful Essays
  • Better Essays

    Gmo Lab Report

    • 2784 Words
    • 12 Pages

    Sylvia R. M. Broeders, Sigrid C. J. De Keersmaecker, and Nancy H. C. Roosen. "How to Deal with the Upcoming Challenges in." Journal of Biomedicine and Biotechnolog (2012): 11.…

    • 2784 Words
    • 12 Pages
    Better Essays
  • Good Essays

    Health Care Provider

    • 1280 Words
    • 6 Pages

    National Center for Biotechnology Information. (2006, December). Retrieved April 7, 2013, from Health for All in the 21st Century: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698153/…

    • 1280 Words
    • 6 Pages
    Good Essays
  • Powerful Essays

    The first two alternatives were somewhat consistent with Abgenix’ past business model that yielded revenues in two ways: 1) by issuing exclusive licenses to use XenoMouse for drug development targeting specific diseases to leading pharmaceutical and biotechnology companies and 2) by undertaking the early stages of XenoMouse based drug development and subsequently selling off the rights to further develop and bring the drugs onto the market. In contrast, the “go-it-alone” method would require an expansion of Abgenix’ resource base and capabilities: a more risky approach with the potential of a relatively high value generation.…

    • 1627 Words
    • 7 Pages
    Powerful Essays
  • Good Essays

    A dialog between Ventria and its stakeholders offered the options of prioritizing their long list of projects to the one or two with the greatest likelihood of successful commercialization. Analyzing the medical activate proteins to determine which would be which would be a more successful use for the company. Didn’t meet the demonstrated need was there other company’s already proving this particular product and the methods of…

    • 459 Words
    • 2 Pages
    Good Essays
  • Good Essays

    In the health field, notable are its application is the production of vaccines and therapies that compliment or replace body immune mechanism. This fast growing section of biotechnology offers scientists the prospects of treating previously untreatable diseases and combating difficult to treat pathogens and controlling conditions that arise from the abnormal function of body systems, best examples are diabetes and…

    • 497 Words
    • 2 Pages
    Good Essays
  • Powerful Essays

    The health care industry Provides health products and service which involved the leading technology of life science. It is a fast-growing industry and will continue to grow in the future because of the increasing request to the advanced medical care. The Global Industry Analysis (GIA,2009) predicted that the prescription drug market is value around $897 billion in world economy in 2015, and Asia-Pacific region is expected to have highest growth in prescription drugs.…

    • 1121 Words
    • 5 Pages
    Powerful Essays
  • Good Essays

    Biotechnology had been described as “the chemical processes and products of a range of organisms discovered empirically” (Butterworth-Heinemann, 1991). The main challenge of biotechnologists, with new metabolic processes and their interrelationships being developed, was the inheritance and regulation of synthesized enzymes and myriads. This challenge over the years has been met thanks to molecular genetics which have provided tools for biotechnology use in many areas across healthcare. The future of biotechnology is so promising due to the sophistication of modern biological sciences. It includes introducing genes of plants and animals to create transgenic organisms and developing innovative treatment and therapies for patients suffering from chronic disease. New and…

    • 1760 Words
    • 8 Pages
    Good Essays
  • Good Essays

    In the past decade, increasing amounts of dollars have been spent on drug development yet the amount of new drugs entering the market per year remains the same. Furthermore with 200 billion dollars of patents expiring in the past four years (Witty, 2010), innovative pharmaceutical companies will need to look at new approaches to discover drugs. With the human genome being sequenced in 2003, a new field of science was created and an optimistic future for drug discovery.…

    • 944 Words
    • 4 Pages
    Good Essays
  • Powerful Essays

    “Biotechnology in a powerful currency, stronger than the Euro or the Dollar, and what’s more, the only hardware you need is the human brain – let’s use our billion brains to our advantage.” – Kiran Mazumdar-Shaw, Founder and Chairman of Biocon, India’s first and largest biotechnology company…

    • 5658 Words
    • 23 Pages
    Powerful Essays